Shionogi’s COVID-19 treatment Xocova has been found to reduce the risk of developing at least one long-lasting COVID-19 symptom, the Osaka-based pharmaceutical company said Wednesday.
Shionogi, which has yet to publish the results in a journal, presented the data at a conference in the United States this week.
Data were obtained through follow-up of mild or moderate COVID-19 patients enrolled in clinical trials. Approval of Xocova as a treatment for virusesThe drug received emergency approval in Japan in November, being the third oral treatment available in the country and the first to be developed domestically.
In an age of misinformation and information overload, Quality journalism is more important than ever.
Subscribing will help you get the story right.